Celenia Stanford
Medical · Lafayette, LANPI 1225518871
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 437 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 437 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$1K
- AbbVie$1K
- Amgen$459
- Lilly USA, LLC$410
- Novo Nordisk$376
- plus $3K from 34 others
What the payments were for
- Food & beverage$7,461100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 78 | $1,184 |
| AstraZeneca | 57 | $1,076 |
| AbbVie | 65 | $1,041 |
| Amgen | 28 | $459 |
| Lilly USA, LLC | 26 | $410 |
| Novo Nordisk | 24 | $376 |
| Axsome Therapeutics, Inc. | 6 | $320 |
| Antares Pharma, Inc. | 10 | $201 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $197 |
| Esperion Therapeutics, Inc. | 12 | $180 |
| Shield Therapeutics Inc | 18 | $159 |
| Corium, LLC | 14 | $159 |
| Alkermes, Inc. | 1 | $125 |
| Exact Sciences | 7 | $118 |
| Otsuka America Pharmaceutical, Inc. | 1 | $111 |
| Sanofi-aventis U.S. LLC | 7 | $110 |
| Noven Therapeutics, LLC | 5 | $105 |
| Merck | 7 | $94 |
| Astellas Pharma US Inc | 6 | $94 |
| Verona Pharma, Inc. | 4 | $93 |
| Dexcom, Inc. | 3 | $83 |
| Bayer | 5 | $82 |
| Pfizer | 4 | $79 |
| Amarin Pharma, Inc. | 5 | $77 |
| Valinor Pharma, LLC | 4 | $72 |
| Johnson & Johnson | 4 | $64 |
| Idorsia Pharmaceuticals US Inc | 3 | $52 |
| Tolmar, Inc. | 3 | $49 |
| Abbott | 2 | $45 |
| Phathom Pharmaceuticals, Inc. | 3 | $42 |
| Ardelyx, Inc. | 2 | $40 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $31 |
| Tris Pharma Inc | 2 | $30 |
| Viatris Specialty LLC | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
| Clarus Therapeutics Inc. | 1 | $13 |
| Acerus Pharmaceuticals Corporation | 1 | $13 |
| Eisai Inc. | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,461 in reported general payments places this provider in the 90th percentile of 253 medical providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 23 | $23,695 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $22,172 |
| Repatha SureclickEvolocumab | 22 | $12,086 |
| FarxigaDapagliflozin Propanediol | 11 | $9,197 |
| Gabapentin | 68 | $1,228 |
| Atorvastatin Calcium | 98 | $996 |
| Levothyroxine Sodium | 69 | $810 |
| Rosuvastatin Calcium | 53 | $757 |
| Glipizide ErGlipizide | 57 | $702 |
| Amlodipine Besylate | 123 | $601 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 33 | $548 |
| Omeprazole | 29 | $446 |
| Duloxetine Hcl | 33 | $423 |
| Fluticasone Propionate | 33 | $422 |
| Donepezil Hcl | 27 | $381 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $410 | $23,69523 claims |
| GSKTrelegy Ellipta | $1,184 | $22,17226 claims |
| AstraZenecaFarxiga | $1,076 | $9,19711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 253 medical providers in Louisiana.
Other medical in Lafayette
- Thomas BriscoeLafayette$13K
- Victoria PlaucheLafayette$6K
- Eric BullerLafayette$6K
- Mary CaseLafayette$6K
- Ashley ParichLafayette$3K
- Brittany RamirezLafayette$3K
- Kristi RobertBaton Rouge$486K
- Vickie RiceBaton Rouge$19K
- Mary McFerrenShreveport$16K
- Rachel RhinehartJefferson$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.